Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 h ago

CRESCENT BIOPHARMA, INC.: Vestal Point Capital, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Vestal Point Capital, LP amended its Schedule 13G filing on Crescent Biopharma, Inc., updating its beneficial ownership stake with the SEC under accession number 0000902664-26-004580. The filing, submitted to the regulator, revises the investment firm's previously reported position in the biopharma company. Schedule 13G amendments are typically filed by passive investors whose holdings cross or adjust around the 5% threshold, making the disclosure a signal of institutional positioning in the stock. The exact revised share count and percentage were not detailed in the filing summary. Investors will watch for further 13G or 13D filings to gauge whether Vestal Point's stake is building or being trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Vestal Point Capital, LP, Crescent Biopharma, Inc.